Abstract Library

#2081 Preclinical Testing of SSA Compounds in a Model of Pancreatic Neuroendocrine Tumors to Optimize Scheduling and Drug Exposition

Introduction: Somatostatin analogues (SSA) such as Octreotide and Lanreotide have demonstrated a significant benefit in Neuroendocrine Tumors, particularly in the well/moderately differentiated types. Nevertheless, there are still several aspects of SSA treatments that remain unsolved, such as drug exposition in patients and schedule optimization.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Casanovas O

Authors: Martínez-López A, Pinto J, Lachamp L, Cabello F, Cherif-Cheikh R,

Keywords: Somatostatin Analogs, Octreotide, pNETs, dose scheduling.,

#414 Pattern and Clinical Predictors of Lymph Node Involvement in Pancreatic Neuroendocrine Tumors (PanNETs)

Introduction: Pancreatic neuroendocrine tumors (PanNETs) are often indolent neoplasms without pathological lymph node (LN) metastasis (pN1).

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Partelli S, Cherif R, Boninsegna L, Gaujoux S, Crippa S,

Keywords: pancreas, NET, lymph node, metastases, prognosis ,

#353 Pattern and Clinical Predictors of Lymph Node Involvement in Neuroendocrine Neoplasms of the Pancreas

Introduction: Pancreatic neuroendocrine neoplasms (PNENs) are often indolent without pathological lymph node metastasis (pN1). Therefore, in patients with low risk of pN1, a lymphadenectomy could be avoided.

Conference:

Presenting Author:

Authors: Partelli S, Cherif R, Boninsegna L, Gaujoux S, Crippa S,

Keywords: Pancreatic neuroendocrine neoplasms, lymph node metastases, predictors,